AIDS Treatment News logo      

November 11, 2010

Egrifta Gets FDA Approval for HIV-Associated Lipodystrophy

POZ: "Egrifta (tesamorelin) has been approved for the treatment of HIV-associated lipodystrophy, according to a November 10 announcement from the U.S. Food and Drug Administration (FDA). The drug, requiring once-daily injections, was approved to reduce visceral adipose tissue (VAT)— deep belly fat surrounding the liver, stomach and other abdominal organs—in people living with HIV experiencing lipodystrophy, a side effect of antiretroviral (ARV) therapy."

0 comments: